Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2025 / Apr / No Escape for Melanoma
Omics Proteomics Translational Science Clinical Data and AI Mass Spectrometry News and Research

No Escape for Melanoma

High-resolution profiling reveals – and allows researchers to prevent – melanoma’s rapid escape from targeted therapy

04/03/2025 2 min read

Share

Melanoma cells can begin evading targeted therapy within hours of treatment – not by mutating, but by engaging a fast, reversible stress response. That’s the conclusion of a new study published in Cell Systems by researchers at the Institute for Systems Biology (ISB) and MIT, which combines phosphoproteomics and transcriptomics to map the early molecular shifts that precede drug resistance.

Using time-resolved mass spectrometry-based phosphoproteomics and deep RNA sequencing, the team tracked changes in melanoma cells exposed to the BRAF inhibitor vemurafenib. While BRAF-ERK signaling was quickly and durably suppressed as expected, the researchers observed that melanoma cells survived not by reactivating this pathway, but by switching to an alternative route involving SRC family kinases (SFKs).

“We found that while the BRAF-ERK signaling pathway was quickly and durably suppressed, cancer cells did not rely on reactivating ERK to survive,” said co-first author Chunmei Liu in a press release. “Instead, they triggered an alternative SRC family kinase signaling pathway, which promoted cell survival and eventual recovery.”

The study identified that this shift was driven by a rise in reactive oxygen species (ROS) following drug treatment. The ROS surge activated SFK signaling, supporting cell survival in a reversible adaptation process that preceded any genetic resistance. When drug pressure was removed, cells reverted to their original state.

This dynamic escape mechanism was captured only through the high temporal resolution afforded by the study’s analytical approach. As the authors note, conventional single-timepoint analyses would likely miss these transient but clinically significant changes. “Our time-resolved design resolves the temporal order of signaling rewiring,” the paper states, adding that the integrated phosphoproteomic and transcriptomic readouts were key to identifying noncanonical adaptation pathways.

To test the therapeutic implications, the researchers paired vemurafenib with the SFK inhibitor dasatinib. The combination significantly reduced melanoma cell viability and slowed tumour growth in vivo—an effect not seen with either drug alone.

“By adding dasatinib, we blocked this adaptive escape mechanism,” said ISB Associate Professor Wei Wei, co-corresponding author. “This approach has the potential to prolong the effectiveness of BRAF inhibitors and improve patient outcomes.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

The Analytical Scientist Innovation Awards 2024: #7
Omics
The Analytical Scientist Innovation Awards 2024: #7

December 2, 2024

4 min read

Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

The Analytical Scientist Innovation Awards 2024: #4
Omics
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Let Me See That Brain
Omics
Let Me See That Brain

December 9, 2024

1 min read

TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

The Analytical Scientist Innovation Awards 2024
Omics
The Analytical Scientist Innovation Awards 2024

December 11, 2024

10 min read

Meet the products – and the experts – defining analytical innovation in 2024

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.